Genmab — Oktober 2019
-
coincidental
Should we treat smoldering myeloma? A debatehttps://twitter.com/VincentRK/status/1187397174226837504 -
Apropos yesterday.
-
I remember some time ago, we had a debate about this subject. The cause was a minor conflict between haema deps at Danish hospitals on the background of some statistical numbers, that showed that Vejle Sygehus had a better MM-survival than the others. The reason for this was not that Vejle was any "better", but that they started treatment earlier - already in the (high-risk) smoldering phase - and thus got a better survival statistics. Maybe they should give Plesner a call for some advice.
-
Meet Genmab A/S CEO Jan van de Winkel in an online interactive Q&A session about the company and its Q3 Report.
8th of November 16.30 CET . Tilmelding: https://www.proinvestor.com/index.php?p=q-and-a&groupid=107
-
Meet Oncology Venture CFO Henrik Moltke in an online interactive Q&A session about the company and its Q3 Report.
6th of November 16.00 CET. https://www.proinvestor.com/index.php?p=q-and-a&groupid=110 -
D-RVD a potential new standard of care https://twitter.com/slentzsch/status/1187449273933336576?s=21
-
7 reasons NOT to treat smoldering myeloma patients https://twitter.com/slentzsch/status/1187402586154065923?s=21
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind